GBT Picks Up Inclacumab From Roche's Bargain Bin
Five years after the Swiss major presented positive Phase II data on inclacumab as a treatment for patients with acute coronary syndromes, the drug has been snapped up by Global Blood Therapeutics for a tiny upfront fee to be developed for sickle cell disease.
You may also be interested in...
Pfizer has reached a deal to buy Global Blood Therapeutics for $5.4bn, gaining the sickle cell therapy Oxbryta and building on efforts to reach underserved patient groups.
Building on Oxbryta, which is already approved in the US for the rare blood disorder, Global Blood Therapeutics has licensed two sickle cell disease programs from Sanofi.
Biopharma financing reached $14.6 billion in the third quarter, a 15% increase over Q2, while merger and acquisitions, at $7.7 billion (the lowest quarter of the year so far), showed a sharp decline. Alliance value reached $20.3 billion, far exceeding the $13.8 billion from Q2.